Sanofi SA (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 230   

Articles published

SNY 54.97 +0.27 (0.49%)
price chart
Notable Movers- Sanofi SA (ADR) (NYSE:SNY), Total SA (ADR) (NYSE:TOT ...
Sanofi SA (ADR) (NYSE:SNY) announced that The New England Journal of Medicine published positive results from a large-scale, multi-center efficacy trial, which found that Fluzone� High-Dose (Influenza Vaccine) was more efficacious in preventing ...
Stocks on Trader's Radar � Sanofi SA (ADR) (NYSE:SNY), Sequenom, Inc ...
Las Vegas, NV - August 16, 2014 - (TechSonian) �Sanofi SA (ADR)(NYSE:SNY) reported that The New England Journal of Medicine published positive results from a large-scale, multi-center efficacy trial, which found that Fluzone� High-Dose (Influenza ...
Investor's Alert �MGIC Investment Corp. (NYSE:MTG), Sanofi SA (ADR) (NYSE ...
Birmingham, West Midlands - (TechSonian) - 08/29/2014 - Elitestockpicks.comis a Stock newsletter website that provides free daily alerts on hot Moving stocks.
Related articles »  
Sanofi SA Given Neutral Rating at Zacks (SNY)
Sanofi SA (ADR) logo Zacks reissued their neutral rating on shares of Sanofi SA (NYSE:SNY) in a research report released on Monday morning.
Sanofi SA Rating Reiterated by Zacks (SNY)  Watch List News (press release)
Bayer AG Given �Neutral� Rating at Zacks (BAYRY)  Mideast Time
Related articles »  
Investor Takeaway: Petroleo Brasileiro Petrobras SA (ADR) (PBR), NII Holdings ...
They worry that the company's worldwide deal with Sanofi SA (ADR) (NYSE:SNY) may not been good news for their pockets, and there has been little to stop MannKind's stock from falling.
Eye Catching Stocks : MannKind Corp. (NASDAQ:MNKD), Petroleo Brasileiro ...  Markets Insider
Related articles »  
Sanofi Shakes Hand With Mannkind For Its Insulin Inhaler
Sanofi, which will be paying as much as $925 million to Mannkind for this strategic agreement, will be responsible for the commercialization of the drug.
GlaxoSmithKline plc (ADR) (NYSE:GSK) Interested In Acquiring InterMune Inc ...
Tomahawk, WI 08/14/2014 (Basicsmedia) - Europe's biggest drug makers led by the likes of Sanofi SA (ADR) (NYSE:SNY) and GlaxoSmithKline plc (ADR) (NYSE:GSK) are said to be in a race against time, to table bids as they push to acquire InterMune Inc.
Why Would GSK Want InterMune?  Bidness Etc
Option Bulls Active as InterMune Inc (ITMN) Soars On Buyout Buzz  Schaeffers Research (blog)
Related articles »  
MannKind Corporation's Deal With Sanofi Validates Opportunity
MannKind Corporation NASDAQ:MNKD's announcement that it struck a deal with Sanofi SA (ADR) NYSE:SNY is generally being seen as a positive on Wall Street.
Buzz Stocks: Amazon.com, Inc., General Motors Company, MannKind ...  Schaeffers Research (blog)
National Bank of Greece (ADR) (NYSE:NBG) vs. Two Depressed Stocks ...  Markets Emerging
Related articles »  
MannKind Corporation's Afrezza To Compliment Sanofi's Lantus
MannKind Corporation (NASDAQ:MNKD) signed a $925 million worldwide licensing agreement with Sanofi SA (ADR) (NYSE:SNY) (EPA:SAN) on August 11.
Why Making Dramatic Moves? � MannKind Corporation (MNKD), GoPro Inc ...  Markets Emerging
Related articles »  
How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug
Contrary to the market's negativity, the 35/65 profit split for MannKind Corporation (MNKD) and the company's commercial partner Sanofi SA ADR (SNY), respectively, is favorable for both parties. If Afrezza registers blockbuster sales as projected, then ...
Related articles »